MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026GlobeNewsWire · Oct 2, 2026
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell TherapyGlobeNewsWire · Sep 30, 2026
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 13, 2026
MiNK Therapeutics Q2 Earnings Call HighlightsMarketBeat · Aug 13, 2026
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung InjuryGlobeNewsWire · Aug 13, 2026
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business UpdatesGlobeNewsWire · Aug 6, 2026MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.60 | -$0.62 | Miss |
| May 15, 2026 | -$0.77 | -$0.57 | Beat |
| Mar 17, 2026 | -$0.68 | -$0.52 | Beat |
| Nov 14, 2025 | -$0.86 | -$0.65 | Beat |
| Aug 14, 2025 | -$0.55 | -$1.06 | Miss |
| May 15, 2025 | -$0.61 | -$0.70 | Miss |